Generic Name : Taceva
Brand Name : Erlotinib
Manufacturer Name : Cipla India
Product Code : OBP 941
Delivery Days : 10 To 12 Working Days
Composition : Taceva
Strength : 150mg
Packaging : Tablet (Blisters)
Presentation : Bottle Pack
Drug Class : Antineoplastic agents
Prescribed For : Treatment of non-small cell lung cancer and pancreatic cancer
Side Effects : Stomach pain, Bone pain, Breathlessness, Constipation, Cough, Diarrhea, Loss of appetite
| Pack Size/Qty | Price | Price Per Pill or unit | |
| 60 TABLET'S | $398.40 | $6.64 | |
| 30 TABLET'S | $200.70 | $6.69 |
Erlocip 150 MG Tablet is a pharmaceutical product used in the treatment of certain types of cancer. The tablet contains the active ingredient erlotinib hydrochloride, which belongs to a class of drugs known as tyrosine kinase inhibitors. Erlocip is specifically designed to target and inhibit the activity of the epidermal growth factor receptor (EGFR), a protein involved in regulating cell growth.
Erlocip 150 MG Tablet works by interfering with the activity of the epidermal growth factor receptor (EGFR), a protein found on the surface of cells. The mechanism of action involves several key steps:
EGFR Inhibition:
EGFR is a receptor that, when activated, triggers signaling pathways inside cells, leading to processes like cell growth and division. In certain types of cancer, EGFR is often overactive, contributing to uncontrolled cell growth.
Tyrosine Kinase Inhibition:
Erlotinib hydrochloride, the active ingredient in Erlocip, is classified as a tyrosine kinase inhibitor. Tyrosine kinases are enzymes involved in the activation of EGFR. Erlocip specifically targets and inhibits these enzymes.
Blocking Signaling Pathways:
By inhibiting tyrosine kinases, Erlocip blocks the signaling pathways downstream of EGFR. These pathways are vital for regulating various cellular processes, and their dysregulation is a common feature in cancer.
Cell Cycle Arrest and Apoptosis:
Disruption of these signaling pathways can lead to cell cycle arrest, halting the progression of the cell cycle. Additionally, Erlocip may induce apoptosis, which is programmed cell death. This is a mechanism by which damaged or abnormal cells are naturally eliminated from the body.
Selective Action on Cancer Cells:
Importantly, Erlocip exhibits a targeted or selective action. It primarily affects cancer cells that have overactive EGFR, minimizing the impact on normal, healthy cells.
Anti-Cancer Effects:
By interfering with the molecular processes driven by EGFR, Erlocip exerts anti-cancer effects, inhibiting the growth and division of cancer cells.
Specific Indications:
Erlocip is commonly prescribed for the treatment of certain cancers, including non-small cell lung cancer (NSCLC) and pancreatic cancer, where abnormal EGFR activity is often observed.
Ingredients:
Erlocip 150 MG Tablet contains the active ingredient erlotinib hydrochloride. Each tablet typically includes 150 milligrams of erlotinib hydrochloride as the main therapeutic component. In addition to the active ingredient, there may be inactive ingredients (excipients), but these are not usually specified in general information.
Dosage:
Erlocip 150 MG Tablet is prescribed in doses of 150 milligrams. The recommended dosage and administration schedule are determined by healthcare professionals based on various factors, including the type and stage of cancer, patient health, and individual response to treatment.
Key points regarding the use of Erlocip 150 MG Tablets:
Cancer Types: Erlocip is commonly used in the treatment of NSCLC and pancreatic cancer. These are specific types of cancers where the activity of the epidermal growth factor receptor (EGFR) is often implicated in the growth and progression of the disease.
EGFR-Positive Cancers: The targeted therapy provided by Erlocip is particularly effective in cancers where there is an overexpression or abnormal activation of EGFR.
Individualized Treatment Plans: The inclusion of Erlocip in a patient's treatment plan is determined by healthcare professionals after a thorough assessment of the cancer type, stage, and the overall health of the individual.
Under Healthcare Supervision: Patients prescribed Erlocip should be under the care and supervision of experienced healthcare professionals. Regular monitoring and assessments are typically conducted to evaluate treatment effectiveness and manage potential side effects.
Comprehensive Medical History: Individuals should provide a comprehensive medical history to their healthcare providers, including information about existing medical conditions, current medications, and any potential allergies. This information helps healthcare professionals assess the suitability of Erlocip for each patient.
Here are some common mistakes to avoid:
Self-Adjustment of Dosage:
Do not alter the prescribed dosage without consulting your healthcare provider. Changes to the dosage should only be made under their guidance.
Missed Doses:
Strive to adhere to the prescribed schedule, and if you miss a dose, do not double up on the next one. Consult your healthcare provider for guidance on missed doses.
Incorrect Administration:
Swallow Erlocip tablets whole with a full glass of water. Do not crush, break, or chew the tablets unless instructed otherwise by your healthcare provider.
Inconsistent Timing:
Try to take Erlocip at the same time each day to maintain a consistent level of the medication in your system.
Incorrect Timing with Meals:
Follow your healthcare provider's guidance regarding taking Erlocip on an empty stomach. Avoid taking it close to meal times without consulting your healthcare team.
Failure to Report Side Effects:
Promptly report any unusual or severe side effects to your healthcare provider. Do not ignore symptoms that may indicate complications.
Dehydration:
Stay well-hydrated, especially if you experience diarrhea. Dehydration can be a side effect of Erlocip, and maintaining adequate fluid intake is important.
Skipping Regular Check-Ups:
Regular check-ups and monitoring are essential. Do not skip appointments with your healthcare provider, and adhere to recommended tests to evaluate treatment effectiveness.
Ignoring Food Restrictions:
If your healthcare provider advises taking Erlocip on an empty stomach, avoid consuming food close to the time of administration.
Not Providing Comprehensive Medical History:
Ensure you communicate your complete medical history, including existing medical conditions, current medications, and allergies, to your healthcare team. This information is vital for tailoring the treatment plan to your specific needs.
Self-Discontinuation of Treatment:
Do not stop taking Erlocip without consulting your healthcare provider. Abruptly discontinuing the medication can have implications for treatment efficacy.
Online Blue Pills is a leading online pharmacy for all your medical needs. If you want to shop Erlocip 150 MG Tablets online in the USA, Online Blue Pills is your go-to destination. Get medicines at the most affordable prices and quickly delivered across the USA only from Online Blue Pills.
Q: What is Erlocip 150 MG Tablet used for?
A: Erlocip 150 MG Tablet is primarily used in the treatment of certain cancers, including non-small cell lung cancer (NSCLC) and pancreatic cancer. It is a targeted therapy that inhibits the activity of the epidermal growth factor receptor (EGFR), a protein involved in the growth of cancer cells.
Q: How should I take Erlocip 150 MG Tablet?
A: Take Erlocip exactly as prescribed by your healthcare provider. It is usually taken orally on an empty stomach, with a full glass of water. Do not crush, break, or chew the tablets without consulting your healthcare team.
Q: What are the common side effects of Erlocip 150 MG Tablet?
A: Common side effects may include skin rash, diarrhea, fatigue, nausea, vomiting, loss of appetite, infections, dry skin, eye irritation, mouth sores, changes in liver function tests, and hair changes. Report any side effects to your healthcare provider.
Q: Can I adjust the dosage of Erlocip 150 MG Tablet on my own?
A: No, do not alter the prescribed dosage without consulting your healthcare provider. Any changes to the dosage should be made under their guidance.
Q: Can I purchase Erlocip 150 MG Tablets online?
A: Yes, you can purchase Erlocip 150 MG Tablets online. Ensure that you use reputable online pharmacies and follow proper procedures for obtaining prescription medications.
Q: How long should I continue taking Erlocip 150 MG Tablet?
A: The duration of Erlocip treatment is determined by your healthcare provider based on your individual response and the type of cancer being treated. Do not discontinue the medication without consulting your healthcare team.
Q: Can Erlocip 150 MG Tablet be taken during pregnancy?
A: Inform your healthcare provider if you are pregnant, planning to become pregnant, or breastfeeding. The use of Erlocip during pregnancy and breastfeeding will be evaluated, and decisions will be made in consultation with your healthcare team.
Q: Are there any food restrictions with the Erlocip 150 MG Tablet?
A: Follow your healthcare provider's guidance on taking Erlocip on an empty stomach. Avoid consuming food close to the time of administration unless otherwise instructed.
Q: What should I do if I miss a dose of Erlocip 150 MG Tablet?
A: If you miss a dose, take it as soon as you remember, unless it is close to the time for your next scheduled dose. Do not double up on doses. Consult your healthcare provider for guidance on missed doses.
Q: How often will I need to undergo monitoring tests while on the Erlocip 150 MG Tablet?
A: Your healthcare provider will schedule regular monitoring tests, including blood tests to assess liver function. Follow their recommendations for the frequency of these tests.
Common side effects of Erlocip 150 MG Tablets may include:
Skin Rash:
Skin rash is a common side effect of Erlocip. It may range from mild to severe. Inform your healthcare provider if you experience skin changes.
Diarrhea:
Diarrhea is a frequent side effect. Staying well-hydrated and following your healthcare provider's recommendations can help manage this symptom.
Fatigue:
Many individuals may experience fatigue or weakness. Adequate rest and seeking support for daily activities can be beneficial.
Nausea and Vomiting:
Nausea and vomiting are common side effects. Medications to prevent or alleviate these symptoms may be prescribed.
Anorexia (Loss of Appetite):
Loss of appetite can occur. Eating small, frequent meals and including nutrient-rich foods may help manage this side effect.
Infections:
Erlocip may increase the risk of infections. Inform your healthcare provider if you develop signs of infection, such as fever or persistent cough.
Dry Skin:
Dry skin or itching may occur. Moisturizers and mild skincare products may be recommended to alleviate these symptoms.
Eye Irritation:
Some individuals may experience eye irritation or redness. Inform your healthcare provider if you have persistent eye symptoms.
Mouth Sores:
Mouth sores or ulcers may develop. Good oral hygiene and gentle mouth care practices can help alleviate discomfort.
Changes in Liver Function Tests:
Erlocip may affect liver function, leading to changes in liver enzyme levels. Regular monitoring through blood tests will be conducted.
Hair Changes:
Changes in hair texture or color may occur. Hair loss (alopecia) is a possible side effect, but it is usually temporary.
Here are the key uses of Erlocip 150 MG Tablets:
Non-Small Cell Lung Cancer (NSCLC):
Erlocip is commonly prescribed for individuals diagnosed with non-small cell lung cancer, which is a type of lung cancer. This medication is particularly effective in cases where the cancer cells exhibit abnormal activation of the epidermal growth factor receptor (EGFR).
Pancreatic Cancer:
Erlocip is also used in the treatment of pancreatic cancer. Pancreatic cancer is a type of malignancy that originates in the pancreas, and like NSCLC, abnormal EGFR activity is observed in some cases. Erlocip helps interfere with EGFR-mediated signaling pathways, contributing to the management of pancreatic cancer.
Targeted Therapy:
Erlocip belongs to the class of drugs known as tyrosine kinase inhibitors. It specifically targets and inhibits the activity of EGFR, a protein involved in regulating cell growth. This targeted approach distinguishes it from traditional chemotherapy and aims to disrupt the molecular processes driving cancer growth.
EGFR-Positive Cancers:
The medication is particularly effective in cancers where there is an overexpression or abnormal activation of EGFR. By inhibiting EGFR, Erlocip works to inhibit the abnormal growth and division of cancer cells.
Precision Medicine:
The use of Erlocip exemplifies the trend toward precision medicine in cancer treatment, where therapies are tailored to target specific molecular characteristics of the cancer cells while minimizing the impact on normal, healthy cells.
Here are general instructions on how to use Erlocip:
Prescription and Consultation:
Erlocip 150 MG Tablets are prescription medications. Only use them as directed by your healthcare provider.
Dosage and Schedule:
Take the tablets exactly as prescribed by your healthcare professional. The recommended dosage and administration schedule depend on individual factors such as the type and stage of cancer.
Oral Administration:
Erlocip is taken orally, usually once a day. Swallow the tablet whole with a full glass of water. Do not crush, break, or chew the tablet unless instructed otherwise by your healthcare provider.
Timing with Meals:
Erlocip is typically taken on an empty stomach, either one hour before or two hours after meals. Follow your healthcare provider's instructions regarding food restrictions around the time of administration.
Consistent Timing:
Try to take Erlocip at the same time each day to maintain a consistent level of the medication in your body.
Missed Dose:
If you miss a dose, take it as soon as you remember, unless it is close to the time for your next scheduled dose. Do not double up on doses to make up for a missed one. Consult your healthcare provider for guidance on missed doses.
Regular Monitoring:
Your healthcare provider may conduct regular check-ups and tests to monitor the effectiveness of the treatment and manage potential side effects.
Hydration:
Stay well-hydrated unless otherwise advised by your healthcare provider. Adequate hydration is important, especially if you experience diarrhea.
Adherence to Medical Advice:
Follow all additional instructions and recommendations provided by your healthcare team. Report any side effects or concerns promptly.
Comprehensive Medical History:
Inform your healthcare provider about your complete medical history, including existing medical conditions, current medications, and any allergies. This information helps healthcare professionals assess the suitability of Erlocip for each patient.
The information provided on website is intended for educational purposes only and should not be used as a substitute for professional medical advice. Please consult a qualified healthcare professional for personalized medical advice.
with branches throughout the USA
Your information is in safe hands.
on all standard USA orders over $ 250
